Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights

Rhea-AI Summary

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) will hold a conference call at 8:00 a.m. ET on November 10, 2022, to discuss financial results for the quarter ended September 30, 2022, and provide corporate highlights. Domestic callers can dial (844) 200-6205, and international callers can reach (929) 526-1599 with access code 048610. A live audio webcast will be available on the company's website and archived for 90 days.

Positive

• Aldeyra is conducting late-stage clinical trials for reproxalap targeting dry eye disease.
• ADX-629 is in Phase 2 clinical testing for systemic immune-mediated diseases.

Negative

• None.

 

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, November 10, 2022 to report financial results for the quarter ended September 30, 2022 and discuss recent corporate highlights.

The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers. The access code is 048610. A live audio webcast of the conference call also will be accessible from the “Investors & Media” section of Aldeyra’s website at https://ir.aldeyra.com/.

After the live webcast, the event will remain archived on Aldeyra’s website for 90 days.

About Aldeyra
Aldeyra is a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in late-stage clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 clinical testing for the treatment of systemic immune-mediated diseases. Our pipeline also includes ADX-2191 (methotrexate injection) for intravitreal administration, in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221102006089/en/

Investors & Media

Scott Solomon

Sharon Merrill Associates, Inc.

Tel: (857) 383-2409

ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.

FAQ

When will Aldeyra Therapeutics report its financial results?

Aldeyra Therapeutics will report its financial results on November 10, 2022.

What is the conference call access code for Aldeyra's financial results?

The conference call access code for Aldeyra's financial results is 048610.

What are the lead product candidates of Aldeyra Therapeutics?

The lead product candidates include reproxalap for dry eye disease and ADX-629 for systemic immune-mediated diseases.

How can I listen to Aldeyra's conference call?

You can listen to Aldeyra's conference call via a live audio webcast on their website.